The supplied records describe three separate securities litigation notices rather than one underlying event. The Aevex action covers investors who acquired Class A common stock from April 17 through June 4, 2026, or shares traceable to its April 17 IPO, and alleges an undisclosed early termination of a 180-day lock-up and a secondary offering benefiting Madison. The Datavault AI action covers securities purchases from September 4, 2024, through October 30, 2025, and alleges misleading statements about partnerships, platform trading activity and connections with convicted felon Edward Withrow III. The ARS Pharmaceuticals action covers securities purchases from March 9 through June 24, 2026, and alleges misleading statements about the expected timing of expanded CVS Caremark insurance coverage for its neffy epinephrine nasal spray. No class has been certified in the Datavault AI or ARS Pharmaceuticals cases; investors in all three matters may seek lead plaintiff status, retain counsel or remain absent class members.